Merck inks $200 million deal for Hengrui's midstage heart disease drug

Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region

Lilly launches Mounjaro in India for treatment of obesity and type 2 diabetes

Adults taking Mounjaro with diet and exercise in a controlled clinical trial lost on average 21.8 kg at the highest dose (15mg) and 15.4 kg at the lowest dose (5mg)

Marksans Pharma’s manufacturing facility at Verna, Goa approved by Australian TG

The products will be manufactured in Goa India and marketed & distributed in Australian markets

OneSource Specialty Pharma strengthens its board by appointing new directors

These appointments align with the group’s philosophy of having a strong and independent board with exceptional industry experts, ensuring strategic guidance and effective governance

Glenmark Pharma launches Empagliflozin and its fixed-drug combinations in India

Empagliflozin and its Fixed Drug Combinations (FDCs) have been launched under the brand names Glempa, Glempa –L and Glempa-M

Zynext Ventures invests in Illexcor Therapeutics to advance novel oral therapy for sickle cell disease

Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD

Zydus to acquire majority stake in Amplitude Surgical, France

Amplitude Surgical is a European MedTech leader in high-quality, lower-limb orthopaedic technologies

Bionova opens Fremont process development and pilot plant

Biocon Biologics and Civica collaborate to expand Insulin Aspart access in US

There are 38.4 million people with diabetes in the United States

Venus Remedies secures in-licensing rights from Infex Therapeutics to develop and commercialize MET-X in India

MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies